Literature DB >> 11422768

Risk factors and mortality associated with calciphylaxis in end-stage renal disease.

A R Mazhar1, R J Johnson, D Gillen, J C Stivelman, M J Ryan, C L Davis, C O Stehman-Breen.   

Abstract

BACKGROUND: We conducted a case control study to determine risk factors and mortality associated with calciphylaxis in end-stage renal disease.
METHODS: Cases of calciphylaxis diagnosed between December 1989 and January 2000 were identified. Three controls were identified for each hemodialysis patient, with calciphylaxis matched to the date of initiation of hemodialysis. Laboratory data and medication doses were recorded during the 12 months prior to the date of diagnosis and at the time of diagnosis of calciphylaxis. Conditional logistic regression was used to identify risk factors for calciphylaxis. Cox proportional hazards models were used to estimate the risk of death associated with calciphylaxis.
RESULTS: Nineteen cases and 54 controls were identified. Eighteen patients were hemodialysis patients, and one had a functioning renal allograft. Diagnosis was confirmed by skin biopsy in 16 cases. Women were at a sixfold higher risk of developing calciphylaxis (OR = 6.04, 95% CI 1.62 to 22.6, P = 0.007). There was a 21% lower risk of calciphylaxis associated with each 0.1 g/dL increase in the mean serum albumin during the year prior to diagnosis and at the time of diagnosis of calciphylaxis (OR = 0.79, 95% CI, 0.64 to 0.99, P = 0.037, and OR = 0.80, 95% CI, 0.67 to 0.96, P = 0.019, respectively). There was a 3.51-fold increase in the risk of calciphylaxis associated with each mg/dL increase in the mean serum phosphate during the year prior to diagnosis (95% CI, 0.99 to 12.5, P = 0.052). At the time of diagnosis of calciphylaxis, for each 10 IU/L increment in alkaline phosphatase, the risk of calciphylaxis increased by 19% (OR = 1.19, 95% CI, 1.00 to 1.40, P = 0.045). Body mass index, diabetes, blood pressure, aluminum, and higher dosage of erythropoietin and iron dextran were not independent predictors of calciphylaxis. Calciphylaxis independently increased the risk of death by eightfold (OR = 8.58, 95% CI, 3.26 to 22.6, P < 0.001).
CONCLUSIONS: Female gender, hyperphosphatemia, high alkaline phosphatase, and low serum albumin are risk factors for calciphylaxis. Calciphylaxis is associated with a very high mortality.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422768     DOI: 10.1046/j.1523-1755.2001.00803.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  78 in total

Review 1.  Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis.

Authors:  Sharon M Moe; Neal X Chen
Journal:  Pediatr Nephrol       Date:  2003-10       Impact factor: 3.714

2.  [Analgesic therapy of calciphylaxis with levomethadone : a case study].

Authors:  M Poels; R Joppich; K Gerbershagen; F Wappler
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

3.  Calciphylaxis: evolving concepts.

Authors:  Giovanni Garini; Elisa Galletti; Roberto Ricci; Augusto Vaglio; Carlo Buzio
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 4.  [Calciphylaxis. A call for interdisciplinary cooperation].

Authors:  V M Brandenburg; S Schmitz; J Floege; K Amann; M Ketteler
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

5.  Painful skin ulcers in a hemodialysis patient.

Authors:  Stuart M Sprague
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-07       Impact factor: 8.237

Review 6.  Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication.

Authors:  Sinee Disthabanchong
Journal:  World J Nephrol       Date:  2012-04-06

7.  Calciphylaxis associated with widespread pulmonary calcification.

Authors:  Tarvinder Singh Dhanjal; Suresh B Babu; Gareth Beevers; Robin E Ferner
Journal:  BMJ Case Rep       Date:  2009-03-20

Review 8.  Calciphylaxis: a review.

Authors:  Cynthia M Magro; Richard Simman; Sarah Jackson
Journal:  J Am Col Certif Wound Spec       Date:  2011-03-27

9.  First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.

Authors:  J Perelló; P H Joubert; M D Ferrer; A Z Canals; S Sinha; C Salcedo
Journal:  Br J Clin Pharmacol       Date:  2018-10-03       Impact factor: 4.335

10.  Sodium thiosulfate therapy for calcific uremic arteriolopathy.

Authors:  Sagar U Nigwekar; Steven M Brunelli; Debra Meade; Weiling Wang; Jeffrey Hymes; Eduardo Lacson
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.